登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CTLA-4 >CT4-C82E5

Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

CTLA4,CD152

表达区间及表达系统(Source)

Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag (CT4-C82E5) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Ser 160 (Accession # G7PL88-1). In the region Ala 37 - Ser 160, the AA sequence of Cynomolgus and Rhesus macaque CTLA-4 are homologus.

Predicted N-terminus: Ala 37

Request for sequence

蛋白结构(Molecular Characterization)

Online(Ala 37 - Ser 160) G7PL88-1

This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.

The protein has a calculated MW of 15.9 kDa. The protein migrates as 20-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Biotinylation)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Biotin:Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag (Cat. No. CT4-C82E5) SDS-PAGE gel

Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Human B7-1, Fc Tag (Cat. No. B71-H5259) at 2 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag (Cat. No. CT4-C82E5) with a linear range of 2-31 ng/mL (QC tested).

Protocol

Biotinylated Human  ELISA

Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque CTLA-4, Avitag,His Tag (Cat. No. CT4-C82E5) with a linear range of 2-63 ng/mL (Routinely tested).

Protocol

背景(Background)

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

 

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CTLA-4靶点信息
英文全称:Cytotoxic T-Lymphocyte-Associated Antigen 4
中文全称:细胞毒性T淋巴细胞相关抗原4
种类:Homo sapiens
上市药物数量:3详情
临床药物数量:57详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定